# Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy

> **NCT01887457** · PHASE2 · SUSPENDED · sponsor: **Brynn Chappell** · enrollment: 33 (estimated)

## Conditions studied

- Immunocompromised Patient
- Aspergillosis
- Fusarium

## Interventions

- **DRUG:** VFEND

## Key facts

- **NCT ID:** NCT01887457
- **Lead sponsor:** Brynn Chappell
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2014-09
- **Primary completion:** 2016-11
- **Final completion:** 2016-12
- **Target enrollment:** 33 (ESTIMATED)
- **Why stopped:** Transfer of management of study
- **Last updated:** 2015-10-07

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01887457

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01887457, "Individualisation of Voriconazole Antifungal Therapy Antifungal Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01887457. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*